Trial ID or NCT#

NCT03569293

Status

recruiting iconRECRUITING

Purpose

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe Atopic Dermatitis (AD) who are candidates for systemic therapy.

Official Title

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

Eligibility Criteria

Ages Eligible for Study: 12 Years to 75 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Albert Sean Chiou, MD, MBA
Albert Sean Chiou, MD, MBA
Dermatologist
Clinical Assistant Professor, Dermatology

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM